MedPath

Evaluating the effect of oral iron chelators on markers of renal function in beta-thalassemia major

Phase 2
Conditions
Thalassaemia Major.
Beta thalassemia
Registration Number
IRCT20090111001545N4
Lead Sponsor
Rasht University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
15
Inclusion Criteria

beta thalassemia major patients receiving deferasirox for more than a year
beta thalassemia major patients receiving deferoxamine for more than a year
healthy control group

Exclusion Criteria

previous diagnosis of congenital diseases
previous diagnosis of renal functions diseases
acute sign and symptoms of acute kidney disease

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Renal function markers. Timepoint: after on year treatment. Method of measurement: ELISA.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath